PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
Recruiting
Observational Study
Atrial Fibrillation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 750 (estimated)
- Sponsor
- University Hospital, Lille · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood.
The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a p…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient undergoing atrial fibrillation catheter ablation
* Able to give their consent
Exclusion Criteria:
* Childs
* Patient under guardianship
* Patients unable to give their consent
* Pregnancy
Contacts